Partnership Between AOP Orphan and Ferrer: Joint Marketing of Adasuve in CEE

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve (Staccato Loxapine) in Central and Eastern Europe.

Adasuve has been developed to provide rapid treatment for agitation in patients suffering from schizophrenia or manic depression. It combines the patented Staccato system with loxapine, a well-established anti-psychotic.

The Staccato system — a hand-held, single-dose inhaler — allows the active agent to reach the lungs very quickly, meaning that it works just as swiftly as an intravenous injection. Consequently, Adasuve is an easy-to-use and very reliable form of inhalation therapy, which quickly relieves the patient’s agitation.

The Austrian pharmaceutical company AOP Orphan markets Adasuve in Austria, Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Switzerland, Slovakia and Slovenia. Other regions are currently being discussed. With this partnership, AOP Orphan has once again demonstrated its innovative spirit and ability to expand. “There is a very large clinical demand for this indication, which up to now has not been met, and we strongly believe that this untapped market will meet the forecast growth expectations,” says Dr Rudolf Widmann, founder and CEO of AOP Orphan. “Adasuve represents a breakthrough in the treatment of agitation and will fundamentally change the way in which psychiatrists treat such patients.”